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Abstract
Background: Dry eye disease (DED) is multifactorial, affecting 5–34 % of the global adult population and reducing
quality of life. The artificial tears or lubricants are the therapy most used for the treatment of DED, due to their low
side effect profile, which attempt to modify the properties of the tear film. The aim of the present study was to
evaluate the clinical efficacy of a fixed combination of xanthan gum and chondroitin sulfate preservative free on
the ocular surface of patients with dry eye disease during 60 days of intervention.
Methods: A phase III, double-blind, masked, controlled, multicenter, clinical trial of 148 subjects, randomized to
either a fixed combination of xanthan gum 0.09 % and chondroitin sulfate 0.1 % (XG/CS) ophthalmic solution
(n = 76) or a fixed combination of polyethylene glycol 400 0.4 % and propylene glycol 0.3 % (PEG/PG) (n = 72). Subjects
self-dosed four times daily during 60 days. Follow-up was set on days 2, 7, 15, 30 and 60. Assessments of
anterior/posterior segment ocular signs were performed. The outcome measures included Schirmer test, tear
film break-up time and OSDI score. Security variables included intraocular pressure, lisamine green and fluorescein
ocular surface stains.
Results: The primary efficacy endpoints were similar between groups at baseline. After intervention time Schirmer test
increased in both groups compared to baseline, XG/CS (6.4 ± 2.2 vs 11.0 ± 6.6; p = 0.002) and PEG/PG (6.5 ± 2.5 vs 10.5
± 5.6; p = 0.019) respectively. Similar results were reported in the tear film break-up time in XG/CS (5.5 ± 2.1 vs 7.4 ± 2.9;
p = 0.027) and PEG/PG (5.2 ± 2.0 vs 7.4 ± 2.7; p = 0.046) respectively. The OSDI score decreased to normal values in both
groups, XG/CS (19.3 ± 7.4 vs 7.3 ± 5.9; p = 0.001) and PEG/PG (19.3 ± 7.5 vs 7.9 ± 8.2; p = 0.001) respectively. There was
no significant difference between treatments for any parameter. Moreover, both groups decreased the presence of
burning sensation, tearing, foreign body sensation, conjunctival hyperemia and photophobia. The adverse events were
not related to the interventions.
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Conclusions: Xanthan gum/chondroitin sulfate preservative free showed similar clinical efficacy, evaluated with OSDI
score, TBUT and Schirmer test compared to polyethylene glycol/propylene glycol in the treatment of dry eye disease.
Trial registration: ClinicalTrials.gov: NCT01657253. Date of registration May 19, 2014.
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Background
The tear film is classically schemed as a three-phase
emulsion, composed by an aqueous, a mucinous and a
lipid layer; together have viscoelastic properties that al-
lows them to adhere to the ocular surface in order to
provide moisture, protection, nutrition and effects in op-
tical quality. However, each layer have a particular func-
tion; the mucin layer, produced by goblet cells, plays an
important role in protecting the ocular surface, stabiliz-
ing tears and acting as a gel-like barrier. The quality and
quantity from the tear film is highly influenced by the
conditions and abnormalities of the ocular surface [1–3].
Alterations to produce good quality of tears or a suffi-
cient amount of tears involve abnormalities in the ocular
surface [4]. Dry eye disease (DED) is multifactorial,
affecting 5–34 % of the global adult population and re-
ducing quality of life [5]. Altered mucin production can
reduce tear film stability, increase osmolarity, and can to
ignite an inflammation response that perpetuates a
vicious circle of disease progression [6].
The artificial tears or lubricants are the therapy most
used for the treatment of DED [7], due to their low side
effect profile, which attempt to modify the properties of
the tear film with the objective to increase their ocular
residence time or restore the affected layer. However,
this therapy must be preservative free due to adverse
effects on ocular surface of the most preservatives used
in Ophthalmology.
Xanthan gum is an exopolysaccharide with rheo-
logical properties that could provide stability and in-
crease the residence time of the tear film on the
ocular surface [8, 9]. Chondroitin sulfate used in oph-
thalmology is a Newtonian fluid that adheres readily
to the surface epithelium and slows the evaporation
of the aqueous layer [10–12]. These pharmacologic
characteristics can to act in a synergistic way and
reinforce the properties of tear film. Previously,
Llamas-Moreno et al. [13] demonstrated that ophthal-
mic solution with XG/CS preservative free was effect-
ive in the treatment of dry eye disease decreasing
OSDI score to normal values. However, due to a
small sample there were not statistically differences in
TBUT and Schirmer test compared with PEG/PG. In
other hand, PEG/PG has showed its efficacy and
safety in the treatment of DED due to restructures
the tear film by forming a gel matrix that provides
long-lasting protection. In this context, both lubri-
cants can to increase the residence time of the tear
film by different mechanisms. XG/CS preservative free
is an option in the treatment of DED with the advan-
tage of protects the ocular surface.
The aim of the study was to evaluate the safety and
efficacy of the fixed combination of XG/CS preservative
free in subjects diagnosed with mild to moderate dry eye
disease in Latin American population compared with
PEG/PG.
Methods
A parallel, randomized, double blind, active-controlled,
multicenter, clinical trial was designed to compare the
efficacy of two ophthalmic solutions. The study was con-
ducted across 7 investigative sites (5 in Mexico, 1 in
Colombia and, 1 in Chile). An ethics committee in each
center reviewed and approved the study. The clinical
trial was conducted in accordance with Good Clinical
Practice Standards (as described by the International
Conference of Harmonisation) and Declaration of
Helsinki. All patients provided written informed consent.
The study was registered at ClinicalTrials.gov with the
identifier number NCT01657253.
Inclusion criteria were patients (aged >18 years) with
best corrected visual acuity < 0.6 logMAR or better in
both eyes, mild to moderate dry eye disease based on
Ocular Surface Disease Index (OSDI) score between
12–45 and without active ocular disease and no use
of topical ocular drops within approximately 24 h
before screening. Exclusion criteria were patients with
autoimmune disease (eg, Sjögren syndrome, etc.)
Meiboian gland dysfunction, blepharitis, corneal dys-
trophy, eyelid malformations, history of eye surgery
within 3 months before baseline, intolerance or
hypersensitivity to any component of study treat-
ments, contact lens users, participation in an investi-
gational drug or device study < 60 days before
screening, ocular o systemic infections or conditions
(eg, epithelial herpes simplex keratitis, vaccinia, vari-
cella or mycobacterial infection; fungal disease; iritis)
that preclude safe administration of study treatment,
and patients that were pregnant, at risk for pregnancy
without birth control treatment, or breastfeeding.
Written informed consent was received from each
subject prior to any study related procedure. Patients
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were randomly allocated 1:1 to received XG/CS (Xiel
ofteno®, Sophia Laboratories, SA de CV, Zapopan,
Jalisco, Mexico) or PEG/PG (Systane®, Alcon Labora-
tories, Inc, Fort Worth, TX, USA) using random
numbers software. Baseline data including demographics,
relevant medical and ocular history, and concomitant
medications were noted at visit 1 (Day 0). Subjects in-
stilled one drop of study drug topically in the inferior con-
junctival sac of both eyes four times daily. The
compliance was evaluated according this formula: weight
of the bottle after intervention × 100 / weight of the bottle
before intervention was started. An adequate compliance
was considered >80 %. The compliance was evaluated in 1
bottle each 30 days. The final compliance was determined
using the mean of both bottles. Moreover, the pharmacist
verified the register of eyedrop instillation from patient
diary. Investigators were masked to the study medication.
Because the active control bottle (Systane) was visibly dif-
ferent than the investigational bottle, a designee at each
study site, other than the investigator, was responsible for
the dispensing study treatment. Attempts were made to
mask the subjects by removing commercial labeling, re-
placing it with identical investigational labels and pack-
aging in identical kit boxes and were separated during the
evaluations. Patients were evaluated during six study visits:
Visit 2 (Day 2 ± 1), Visit 3 (Day 7 ± 1), Visit 4 (Day 15 ± 1),
Visit 5 (Day 30 ± 1) and, Visit 6 (Day 60 ± 1) after
randomization. Clinical assessments during baseline and
the final visit consisted of intraocular pressure (IOP),
using a calibrated Goldman applanation tonometer, tear
break-up time (TBUT), Schirmer I test with anesthesia,
and indirect ophthalmoscopy. Slit lamp assessment (bio-
microscopy) and fluorescein and green lisamine stain were
performed. Safety assessments included adverse events
(AEs) and ocular tolerability (burning sensation, tearing,
foreign body sensation, conjunctival hyperemia and
photophobia).
The primary efficacy endpoints were the increase from
baseline in mean Schirmer test, TBUT and, a reduction
of OSDI score at visit 6 (Day 60). The safety endpoint
was the incidence of ocular and systemic AEs and their
severity and relationship to the study drug.
Statistical analysis
The results are presented in mean and standard devi-
ation. Kolmogorov-Smirnov test was made to know the
normal distribution of data. We considered both eyes for
statistical analysis. An intent-to-treat analysis was per-
formed. Inter-eye correlation was made within the same
subject. The mean of IOP, Schirmer test, TBUT and
OSDI score were compared using paired two-sided t
tests. Ocular signs and symptoms were summarized
using proportions and were analyzed with the chi-square
method. In all analyses, a p- value of < 0.05 (two-tailed)
was considered statistically significant. Adverse reactions
were evaluated using the collection method. All statis-
tical analyses were conducted using SPSS software (IBM
Corporation. Armonk, NY, USA) version 19.
Results
The treatment groups were comparable regarding to demo-
graphics and baseline characteristics (Table 1). Of the 190
subjects screened, 183 subjects were randomized (n = 93,
XG/CS; n = 90 PEG/PG) and 148 subjects completed the
study (n = 76, XG/CS; n = 72, PEG/PG) without statistical
difference. According to Kolmogorov-Smirnov test the data
Table 1 Demographics and clinical characteristics in three Latin American populations at baseline
Chile Colombia Mexico
XG/CS n = 32 PEG/PG n = 24 pa XG/CS n = 26 PEG/PG n = 20 pa XG/CS n = 94 PEG/PG n = 100 pb
Age, years
Mean (SD) 38.6 (13.6) 35.3 (11.8) 0.336 52.9 (13.7) 52.7 (12.4) 0.824 50.8 (16.7) 48.3 (13.5) 0.273
Gender, N (%)
Female 13 (81) 8 (67) 0.212 10 (77) 8 (80) 0.802 20 (77) 16 (80) 0.958
Male 3 (19) 4 (33) 3 (23) 2 (20) 6 (23) 4 (20)
IOP, mmHg
Mean (SD) 14.2 (2.5) 13.7 (1.2) 0.471 12.5 (2.3) 13.2 (1.6) 0.535 12.8 (2.5) 13.1 (2.4) 0.201
Schirmer test, mm/min
Mean (SD) 6.2 (2.4) 7.1 (2.6) 0.114 6.0 (2.8) 6.3 (2.8) 0.674 6.8 (1.8) 6.2 (2.4) 0.233
TBUT, sec
Mean (SD) 5.5 (1.3) 6.0 (1.8) 0.292 4.9 (2.0) 4.5 (2.0) 0.487 5.8 (2.2) 4.9 (1.9) 0.073
OSDI, score
Mean (SD) 18.5 (6.6) 20.0 (9.2) 0.714 19.8 (7.9) 15.4 (2.4) 0.070 19.4 (6.9) 20.6 (7.4) 0.234
XG/CS Xanthan gum/Chondroitin sulfate, PEG/PG Polyethylene glycol/Propylene glycol, IOP Intraocular pressure, TBUT Tear break-up time, OSDI Ocular Surface
Disease Index. aWilcoxon T test. bPaired T test. p ≤ 0.05. n = total eyes
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have a normal distribution. The primary efficacy endpoints
were similar between groups at baseline. After intervention
time, Schirmer test and TBUT increased in both groups
compared with baseline (Figs. 1 and 2). The OSDI score
decreased to normal values in both groups (Fig. 3). There
were not significance differences to compare groups. More-
over, both groups decreased the presence of burning sensa-
tion, XG/CS (77 to 48 %; p = 0.007), PEG/PG (72 to 34 %;
p = 0.006); tearing, XG/CS (50 to 23 %; p = 0.027), PEG/PG
(28 to 17 %; p = 0.006); foreign body sensation, XG/CS (79
to 29 %; p = 0.027), PEG/PG (80 to 28 %; p = 0.027);
conjunctival hyperemia XG/CS (59 to 28 %; p = 0.007),
PEG/PG (73 to 35 %; p = 0.007); and photophobia, XG/CS
(58 to 31 %; p = 0.027), PEG/PG (80 to 29 %; p = 0.027).
There were no alterations in corneal stains. The adverse
events were not related to the interventions.
Discussion
The ideal lubricant should be able to restore the affected
component of tear film regardless etiology, with less fre-
quency of instillation, and above all non adverse effects
on the ocular surface [14–16]. A main limitation of arti-
ficial tears available is the short duration of symptom
relief due to restricted precorneal residence time.
Xanthan gum is a polymer with mucoadhesive proper-
ties that creates synergic interactions with mucin mole-
cules playing an important role in the formation of the
mucus layer of the tear film [17]. In addition, like others
polysaccharides, has a high affinity for water and is able
to increase viscosity [18, 19]. Regardless of this charac-
teristic, XG alone or in combination has been tested
poorly in clinical practice. The pharmacology profile of
xanthan gum in combination with sodium hyaluronate
Fig. 1 Schirmer test before and after intervention in both groups. Schirmer test after intervention showed statistically significant difference
compared to baseline in XG/CS (p = 0.002) and PEG/PG (p = 0.019) but not between them
Fig. 2 TBUT before and after intervention in both groups. TBUT after intervention showed statistically significant difference compared to baseline
in XG/CS (p = 0.027) and PEG/PG (p = 0.046) but not between them
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has been explored in the treatment of corneal abrasions
showing efficacy and protection of the ocular surface
after 7 days of intervention. Faraldi et al., concluded the
importance of hydration and protection of the cornea
due to water binding and mucoadhesivity properties pro-
vided by XG and sodium hyaluronate [20]. Moreover
Llamas-Moreno et al. demonstrated the clinical efficacy
of XG/CS in patients with similar characteristics, im-
proving OSDI score compared to PEG/PH-HP Guar.
This significant change in OSDI score reach to normal
values, showing the importance of the increase in the
residence time of a lubricant. However not significant
changes either TBUT or Schirmer test were reported
between groups.
In other hand, PEG/PG works by binding to the
hydrophobic exposed areas of the epithelial cells, attach-
ing a protective HP-Guar tear-gel matrix that helps re-
store the ocular surface. In a review, PEG/PG has
showed in several clinical trials its efficacy and safety
studies compared with different lubricants.
Clinical symptoms, TBUT, Schirmer test, and OSDI
score are the most sensitive and specific tests per-
formed to evaluate the severity of DES [7, 21].
Changes in these parameters help to understand the
clinical efficacy of a treatment. In the current study,
the group that received XG/CS improved its results
in all tests above mentioned. However, there were no
differences when was compared with PEG/PG after
60 days of intervention.
These results could be due to mucoadhesivity prop-
erties of xanthan gum, which increased the corneal
residence time of the tear film. On the other hand,
CS has moisturizing properties delaying evaporation
of aqueous layer due to its effect like-coat on the
ocular surface [22–24].
In addition to rheological properties above described,
both, XG and CS act on different pathophysiological
points involved in DED development. Xanthan gum is
rich in OH-groups allowing it to react with reactive
oxygen species and preventing oxidative stress damage
implicated as a possible pathogenic cause of DED [25].
Meanwhile, CS modulates the inflammatory response
mediated by cytokines [23].
One limitation of this study is the lack of measure-
ment of some inflammatory and oxidative markers
described in the pathogenesis of DED [26, 27].
Conclusions
Xanthan gum/chondroitin sulfate preservative free showed
similar clinical efficacy, evaluated with OSDI score, TBUT
and Schirmer test compared to polyethylene glycol/propyl-
ene glycol in the treatment of dry eye disease.
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